# The Effect of a New Antioxidant Combination (ASTED) on Moderate to Severe Thyroid Eye Disease

> **NCT02422368** · PHASE2,PHASE3 · WITHDRAWN · sponsor: **Iran University of Medical Sciences**

## Conditions studied

- Thyroid Eye Disease

## Interventions

- **DRUG:** Methylprednisolone + ASTED
- **DRUG:** Methylprednisolone +Placebo

## Key facts

- **NCT ID:** NCT02422368
- **Lead sponsor:** Iran University of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-09-01
- **Primary completion:** 2024-06
- **Final completion:** 2024-11
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Do not access to the drug
- **Last updated:** 2022-01-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02422368

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02422368, "The Effect of a New Antioxidant Combination (ASTED) on Moderate to Severe Thyroid Eye Disease". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT02422368. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*